contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


analyst-group-analyst-group-comment-on-circios-in-vivo-car-m-collaboration-with-united-immunity

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Circio Holding

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 26th of March 2026, that the Company has entered a research collaboration with United Immunity Co., Ltd. (”United Immunity”),...

<div class="mfn-preamble">Circio Holding ASA (”Circio” or ”the Company”) announced, on the 26th of March 2026, that the Company has entered a research collaboration with United Immunity Co., Ltd. (”United Immunity”), a Tokyo-based biotechnology company, to evaluate circVec in the context of in vivo CAR-Macrophage (CAR-M) therapy. Under the collaboration, United Immunity will test whether its proprietary P-LNP delivery platform can deliver circVec to myeloid immune cells, specifically macrophages and dendritic cells, with the aim of establishing a joint platform for in vivo CAR-M applications in cancer, fibrosis, and autoimmune disorders. No financial terms have been disclosed.</div><div class="mfn-body">In summary, Analyst Group views the United Immunity collaboration as a meaningful and technically well-founded addition to Circio’s in vivo cell therapy portfolio. The two technologies address complementary bottlenecks, United Immunity solving the delivery problem, circVec the expression problem, and together could form the basis of a differentiated CAR-M platform. While no financial terms have been disclosed and the CAR-M space remains at an early preclinical stage, Analyst Group regards the collaboration as a longer-term optionality layer that incrementally strengthens circVec’s long-term licensing attractiveness, particularly in light of large pharmaceutical players committing multi-billion dollar capital to the in vivo cell therapy field.<hr><a href="https://analystgroup.se/kommentarer/comment-on-circios-in-vivo-car-m-collaboration-with-united-immunity/" rel="noopener">Read Analyst Group’s comment here</a><hr>About Analyst Group:&nbsp;One of Sweden's leading equity research&nbsp;boutiques with focus on small and medium-sized listed companies. <a href="https://www.analystgroup.se/om-oss/" rel="noopener">Read more about Analyst Group</a> &nbsp; This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.</div>

Analyst Group: Analyst Group Comment on Circio’s In Vivo CAR-M Collaboration with United Immunity

Intervjuer i samband med Stockholm Corporate Finance 17:e Kapitalmarknadsdagar Life Science 2026

Return on capital (ROE, ROI, ROIC, RONIC)

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Finanslingo enkelt förklarat: EBIT, EBITA och EBITDA 

Stora företag är dyrare, men finns det värde i små företag?